Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of age

Trial Identifier: 216156
Sponsor: GlaxoSmithKline
Start Date: November 2022
Primary Completion Date: May 2025
Study Completion Date: May 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BRAZIL Salvador, BRAZIL, 41680-020
FRANCE Lyon, FRANCE, 69004
FRANCE Paris, FRANCE, 75475
FRANCE PIERRE BENITE, FRANCE, 69495
GERMANY Bochum, GERMANY, 44787
GERMANY Frankfurt, GERMANY, 60596
GERMANY Hamburg, GERMANY, 20146
PHILIPPINES Manila, PHILIPPINES, 1000
SOUTH_AFRICA Johannesburg, SOUTH_AFRICA, 2001
SOUTH_AFRICA Soweto, SOUTH_AFRICA, 2013
SPAIN Barcelona, SPAIN, 08015
SPAIN Madrid, SPAIN, 28006
SPAIN Madrid, SPAIN, 28040
SPAIN Valencia, SPAIN, 46026
UNITED_KINGDOM London, UNITED_KINGDOM, WC1E 6JB
UNITED_KINGDOM London, UNITED_KINGDOM, SW10 9NH
UNITED_STATES, DC Washington, DC, UNITED_STATES, 20009
UNITED_STATES, KS Lenexa, KS, UNITED_STATES, 66219
UNITED_STATES, MA Boston, MA, UNITED_STATES, 02215
UNITED_STATES, MO Springfield, MO, UNITED_STATES, 65802
UNITED_STATES, NY Bronx, NY, UNITED_STATES, 10467
UNITED_STATES, PA Pittsburgh, PA, UNITED_STATES, 48202
UNITED_STATES, TX Austin, TX, UNITED_STATES, 78705